CoChat

Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma

Open access

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

Background: Hepatocellular carcinoma (HCC) developed in fibrotic liver does not respond well to immunotherapy, mainly due to the stromal microenvironment and the fibrosis-related immunosuppressive factors. The characteristic of liver sinusoidal endothelial cells (LSECs) in contributing to fibrosis and orchestrating immune response is responsible for the refractory to targeted therapy or immunotherapy of HCC. We aim to seek a new strategy for HCC treatment based on an old drug simvastatin which shows protecting effect on LSEC. Method: The features of LSECs in mouse fibrotic HCC model and human HCC patients were identified by immunofluorescence and scanning electron microscopy. The effect of simvastatin on LSECs and hepatic stellate cells (HSCs) was examined by immunoblotting, quantitative RT-PCR and RNA-seq. LSEC-targeted delivery of simvastatin was designed using nanotechnology. The anti-HCC effect and toxicity of the nano-drug was evaluated in both intra-hepatic and hemi-splenic inoculated mouse fibrotic HCC model. Results: LSEC capillarization is associated with fibrotic HCC progression and poor survival in both murine HCC model and HCC patients. We further found simvastatin restores the quiescence of activated hepatic stellate cells (aHSCs) via stimulation of KLF2-NO signaling in LSECs, and up-regulates the expression of CXCL16 in LSECs. In intrahepatic inoculated fibrotic HCC mouse model, LSEC-targeted nano-delivery of simvastatin not only alleviates LSEC capillarization to regress the stromal microenvironment, but also recruits natural killer T (NKT) cells through CXCL16 to suppress tumor progression. Together with anti-programmed death-1-ligand-1 (anti-PD-L1) antibody, targeted-delivery of simvastatin achieves an improved therapeutic effect in hemi-splenic inoculated advanced-stage HCC model. Conclusions: These findings reveal an immune-based therapeutic mechanism of simvastatin for remodeling immunosuppressive tumor microenvironment, therefore providing a novel strategy in treating HCC. Graphical Abstract:

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12951-021-01205-8

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Liver fibrosis-associated LSEC capillarization contributes to aggressive HCC development. A Schematic diagram of liver fibrosis-associated HCC mouse model. B Tumor growth curve and C Bioluminescence imaging of tumor and representative liver tumor morphology at the endpoint. D Statistical analysis of tumor volume and weight. E Representative pictures of Masson trichrome staining, α-SMA immunofluorescence in mice non-fibrotic and fibrotic liver tissue. Scale bar stands for 50 μm. Yellow dotted line indicates the border between non-tumor and tumor tissue. The quantification of collagen density, α-SMA expression were shown. F LYVE1 and CD31 co-immunofluorescence in mice non-fibrotic and fibrotic liver tissue, scale bar stands for 50 μm. Scanning electron micrographs illustrating the morphological response of LSEC. Scale bar stands for 1 μm. The quantification of LYVE1 and CD31 expression were shown, as well as the porosity and fenestration on LSEC. G Percentage of α-SMA, CD31 fluorescence and tumor weight are pairwise positively correlated. H Kaplan–Meier overall survival and disease-free survival curves of HCC patients with non-fibrotic tumor (n = 26) or fibrotic tumor (n = 38). I Expressions of α-SMA and CD31 in non-fibrotic HCC and fibrotic HCC tissues as determined by immunohistochemistry. Scale bar stands for 50 μm.*p < 0.05, **p < 0.01, ***p < 0.001
Fig. 1 Liver fibrosis-associated LSEC capillarization contributes to aggressive HCC development. A Schematic diagram of liver fibrosis-associated HCC mouse model. B Tumor growth curve and C Bioluminescence imaging of tumor and representative liver tumor morphology at the endpoint. D Statistical analysis of tumor volume and weight. E Representative pictures of Masson trichrome staining, α-SMA immunofluorescence in mice non-fibrotic and fibrotic liver tissue. Scale bar stands for 50 μm. Yellow dotted line indicates the border between non-tumor and tumor tissue. The quantification of collagen density, α-SMA expression were shown. F LYVE1 and CD31 co-immunofluorescence in mice non-fibrotic and fibrotic liver tissue, scale bar stands for 50 μm. Scanning electron micrographs illustrating the morphological response of LSEC. Scale bar stands for 1 μm. The quantification of LYVE1 and CD31 expression were shown, as well as the porosity and fenestration on LSEC. G Percentage of α-SMA, CD31 fluorescence and tumor weight are pairwise positively correlated. H Kaplan–Meier overall survival and disease-free survival curves of HCC patients with non-fibrotic tumor (n = 26) or fibrotic tumor (n = 38). I Expressions of α-SMA and CD31 in non-fibrotic HCC and fibrotic HCC tissues as determined by immunohistochemistry. Scale bar stands for 50 μm.*p < 0.05, **p < 0.01, ***p < 0.001CC BY · PubMed Central
Fig. 2 Simvastatin deactivates HSC via LSEC and recruits NKT cells. A Quantitative RT-PCR analysis and B immunoblotting of KLF2 and eNOS in SK-Hep1 LSEC cells treated with the indicated concentrations of simvastatin for 24 h (n = 3). GAPDH acts as the loading control. C Extracellular concentration of NO upon different doses of simvastatin treatment (n = 3). D Quantitative RT-PCR analysis and, E immunoblotting of ACTA2 and COL1 in LPS-activated LX2 treated with the supernatant of SK-Hep1 upon different doses of simvastatin treatment with or without L-NAME (n = 3). GAPDH acts as the loading control. F Gene expression profiles of chemokines analyzed with RNA-seq data which derived from SK-Hep1 cells treated with simvastatin or control. Simvastatin-responsive chemokine genes were grouped in association with clusters of various immune cell-regulating functions. The p value of each comparison was indicated with colors. G Quantitative RT-PCR analysis and H immunoblotting of CXCL16 in SK-Hep1 cells treated with the indicated concentrations of simvastatin for 24 h (n = 3). GAPDH acts as the loading control. I CXCR6 expression was detected in NKT cells. J The expression of CD69 and IFN-γ was detected in NKT cells treated with control, simvastatin, the co-culture with SK-Hep1 cells, and the combination, respectively (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001, n.s. = not significant
Fig. 2 Simvastatin deactivates HSC via LSEC and recruits NKT cells. A Quantitative RT-PCR analysis and B immunoblotting of KLF2 and eNOS in SK-Hep1 LSEC cells treated with the indicated concentrations of simvastatin for 24 h (n = 3). GAPDH acts as the loading control. C Extracellular concentration of NO upon different doses of simvastatin treatment (n = 3). D Quantitative RT-PCR analysis and, E immunoblotting of ACTA2 and COL1 in LPS-activated LX2 treated with the supernatant of SK-Hep1 upon different doses of simvastatin treatment with or without L-NAME (n = 3). GAPDH acts as the loading control. F Gene expression profiles of chemokines analyzed with RNA-seq data which derived from SK-Hep1 cells treated with simvastatin or control. Simvastatin-responsive chemokine genes were grouped in association with clusters of various immune cell-regulating functions. The p value of each comparison was indicated with colors. G Quantitative RT-PCR analysis and H immunoblotting of CXCL16 in SK-Hep1 cells treated with the indicated concentrations of simvastatin for 24 h (n = 3). GAPDH acts as the loading control. I CXCR6 expression was detected in NKT cells. J The expression of CD69 and IFN-γ was detected in NKT cells treated with control, simvastatin, the co-culture with SK-Hep1 cells, and the combination, respectively (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001, n.s. = not significantCC BY · PubMed Central
Fig. 3 Simvastatin LSEC-targeted delivery NP platform was designed. A Efficient co-encapsulation of simvastatin into PLGA NP using a solvent displacement technique. B TEM images of PLGA NPs loaded with simvastatin cores. C Particle size of the PLGA NP. D Zeta Potential of the PLGA NP. E Images and F quantification of the DiD-loaded PLGA (DiD/PLGA-PEG) and mannan conjugated PLGA(DiD/PLGA-PEG-MAN) in liver with tumor and other major organs at 24 h after injection in mice bearing Hepa1-6 liver tumor. G Fluorescence imaging detecting DiD in PLGA-PEG or mannan-coated PLGA-PEG and LSEC marked with CD31, scale bar stands for 50 μm. *p < 0.05, **p < 0.01, ***p < 0.001, n.s. = not significant
Fig. 3 Simvastatin LSEC-targeted delivery NP platform was designed. A Efficient co-encapsulation of simvastatin into PLGA NP using a solvent displacement technique. B TEM images of PLGA NPs loaded with simvastatin cores. C Particle size of the PLGA NP. D Zeta Potential of the PLGA NP. E Images and F quantification of the DiD-loaded PLGA (DiD/PLGA-PEG) and mannan conjugated PLGA(DiD/PLGA-PEG-MAN) in liver with tumor and other major organs at 24 h after injection in mice bearing Hepa1-6 liver tumor. G Fluorescence imaging detecting DiD in PLGA-PEG or mannan-coated PLGA-PEG and LSEC marked with CD31, scale bar stands for 50 μm. *p < 0.05, **p < 0.01, ***p < 0.001, n.s. = not significantCC BY · PubMed Central
Fig. 4 Simvastatin NPs suppress HCC development. A Tumor inoculation and treatment scheme. B Bioluminescence imaging of Hepa1-6 tumor bearing mice during tumor progression in various treatment groups. C Tumor growth curves and, D survival curves of Hepa1-6 tumor bearing mice in various treatment groups (n = 5). E Representative image of liver with Hepa1-6 tumor and quantification of liver weight at day 21 after inoculation (n = 3). Scale bar stands for 1 cm. *p < 0.05, **p < 0.01, ***p < 0.001, n.s. = not significant
Fig. 4 Simvastatin NPs suppress HCC development. A Tumor inoculation and treatment scheme. B Bioluminescence imaging of Hepa1-6 tumor bearing mice during tumor progression in various treatment groups. C Tumor growth curves and, D survival curves of Hepa1-6 tumor bearing mice in various treatment groups (n = 5). E Representative image of liver with Hepa1-6 tumor and quantification of liver weight at day 21 after inoculation (n = 3). Scale bar stands for 1 cm. *p < 0.05, **p < 0.01, ***p < 0.001, n.s. = not significantCC BY · PubMed Central
Fig. 5 Simvastatin NPs remodel tumor microenvironment in fibrotic HCC. A HE staining of tissue features from HCC mice with various treatments. Yellow dotted line indicates the border between normal liver and tumor tissue. The left side is non-tumor liver tissue and right side is tumor tissue. Representative images are shown. Scale bar stands for 50 μm. B Masson trichrome (MT) staining shown together with αSMA fluorescence staining in liver tissues. Data are presented as mean ± SD. Scale bar in MT image stands for 20 μm, in IF image stands for 50 μm. C LYVE1 and CD31 expression by fluorescence staining shown together with LSEC feature using SEM in liver tissues. The quantification of porosity and fenestration of LSEC is shown (n = 5). Scale bar in IF image stands for 50 μm, in SEM image stands for 1 μm. D Quantitative RT-PCR analysis of Klf2 and Nos3 in LSECs extracted from liver tissues intervened with various treatments (n = 5). E The fluorescence staining of LYVE1 and CD31. Scale bar stands for 50 μm. F NKT cell frequency in liver tissues detected by flow cytometry (n = 5). G CD69+ and IFN-γ+ levels of hepatic NKT cells detected by flow cytometry (n = 5). H mRNA expression of chemokines and cytokines detected by real-time PCR in tumors in various treatment groups (n = 5). I The average number of apoptosis cells per high-power field (HPF) detected by TUNEL immune fluorescence staining. Scale bar stands for 50 μm. J Scheme of immune cell depletion study and tumor growth curves of Hepa1-6 tumor treated with simvastatin NP after anti-CD1d, CD4or CD8 intraperitoneal injection (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001, n.s. = not significant
Fig. 5 Simvastatin NPs remodel tumor microenvironment in fibrotic HCC. A HE staining of tissue features from HCC mice with various treatments. Yellow dotted line indicates the border between normal liver and tumor tissue. The left side is non-tumor liver tissue and right side is tumor tissue. Representative images are shown. Scale bar stands for 50 μm. B Masson trichrome (MT) staining shown together with αSMA fluorescence staining in liver tissues. Data are presented as mean ± SD. Scale bar in MT image stands for 20 μm, in IF image stands for 50 μm. C LYVE1 and CD31 expression by fluorescence staining shown together with LSEC feature using SEM in liver tissues. The quantification of porosity and fenestration of LSEC is shown (n = 5). Scale bar in IF image stands for 50 μm, in SEM image stands for 1 μm. D Quantitative RT-PCR analysis of Klf2 and Nos3 in LSECs extracted from liver tissues intervened with various treatments (n = 5). E The fluorescence staining of LYVE1 and CD31. Scale bar stands for 50 μm. F NKT cell frequency in liver tissues detected by flow cytometry (n = 5). G CD69+ and IFN-γ+ levels of hepatic NKT cells detected by flow cytometry (n = 5). H mRNA expression of chemokines and cytokines detected by real-time PCR in tumors in various treatment groups (n = 5). I The average number of apoptosis cells per high-power field (HPF) detected by TUNEL immune fluorescence staining. Scale bar stands for 50 μm. J Scheme of immune cell depletion study and tumor growth curves of Hepa1-6 tumor treated with simvastatin NP after anti-CD1d, CD4or CD8 intraperitoneal injection (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001, n.s. = not significantCC BY · PubMed Central
Fig. 6 Combination of simvastatin NP and PD-L1 antibody shows synergistic efficacy in advanced HCC suppression. A PD-L1 level of HCC tissues from various treatments and normal liver were measured by flow cytometry. B Mice HCC model establishment and treatment scheme. C Bioluminescence imaging of Hepa1-6 tumor bearing mice in various treatment groups (n = 5). D Tumor growth curves. E Representative liver tumor morphology. Scale bar stands for 1 cm. F Survival curves (n = 5). **p < 0.01, ***p < 0.001, n.s. = not significant
Fig. 6 Combination of simvastatin NP and PD-L1 antibody shows synergistic efficacy in advanced HCC suppression. A PD-L1 level of HCC tissues from various treatments and normal liver were measured by flow cytometry. B Mice HCC model establishment and treatment scheme. C Bioluminescence imaging of Hepa1-6 tumor bearing mice in various treatment groups (n = 5). D Tumor growth curves. E Representative liver tumor morphology. Scale bar stands for 1 cm. F Survival curves (n = 5). **p < 0.01, ***p < 0.001, n.s. = not significantCC BY · PubMed Central
Fig. 7 Schematic representation of the Nano delivery of simvastatin targeting LSECs to remodel HCC microenvironment
Fig. 7 Schematic representation of the Nano delivery of simvastatin targeting LSECs to remodel HCC microenvironmentCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 119

Metadata

Authors
Yu, Z., Guo, J., Liu, Y., Wang, M., Liu, Z., Gao, Y., & Huang, L.
Affiliations
  • University of North Carolina at Chapel Hill (US)
  • Shanghai University of Traditional Chinese Medicine (CN)
Corresponding author
  • Gao, Yueqiu
  • Huang, Leaf
Venue
Journal of Nanobiotechnology
Published
2022-01-04
Volume
20
Issue
1
Pages
9-9
ISSN
1477-3155 (ISSN-L)
OpenAlex
W4205834838
Cited by
114
References
37
Citations by year
2026: 18 · 2025: 34 · 2024: 29 · 2023: 21 · 2022: 12
FWCI
14.30
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Nanobiotechnology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institutes of Health (CA198999)
  • National Natural Science Foundation of China (82074154, 81774240)
  • China Scholarship Council (201808310047)
  • Shanghai Rising-Star Program (17QA1403900)
  • Youth Tip-top Talent program in Shanghai
  • Training Plan of Outstanding Young Medical Talents from Shanghai Municipal Health Bureau (2017YQ021)
  • Siming Scholar from Shanghai Shuguang Hospital (SGXZ-201904)
  • Youth Xinglin Scholar from Shanghai University of Traditional Chinese Medicine
  • Jilin University
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
hepatocellular carcinoma, simvastatin, liver sinusoidal endothelial cells, hepatic stellate cells, tumor microenvironment, liver fibrosis, CXCL16, NKT cells, PD-L1 blockade, immunosuppression, stromal remodeling
MeSH terms
Nanoparticle Drug Delivery System, Animals, Cells, Cultured, Carcinoma, Hepatocellular, Humans, Liver, Liver Neoplasms, Male, Mice, Inbred C57BL, Signal Transduction, Simvastatin, Endothelial Cells, Mice, Nanoparticles, Hepatic Stellate Cells, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma. https://app.cochat.ai/papers/10.1186/s12951-021-01205-8
The paper
Yu, Z., Guo, J., Liu, Y., Wang, M., Liu, Z., Gao, Y., & Huang, L. (2022). Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma. Journal of Nanobiotechnology. https://doi.org/10.1186/s12951-021-01205-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.